Amgen stock slips 4.75% and underperforms rivals

11 articles · Updated · MarketWatch · May 1

Shares closed at $329.82 as trading volume reached 3.8 million, above the 50-day average of 2.6 million.
The decline came in a mixed US market session, with the S&P 500 rising 0.29% while the Dow Jones Industrial Average fell 0.31%.
Amgen ended 15.71% below its 52-week high of $391.29 reached on 2 March, trailing Johnson & Johnson, Pfizer and AbbVie, which posted smaller declines.

With a key drug facing FDA removal, is Amgen's stock now a deeply undervalued opportunity or a falling knife?

Amgen inherited a drug facing fraud claims. How does this scandal redefine risks in multi-billion dollar biotech acquisitions?